CANDEL THERAPEUTICS INC (CADL)
Health Care · Viral immunotherapy / immuno-oncology · NASDAQ
Clinical-stage biopharmaceutical company developing off-the-shelf viral immunotherapies to trigger systemic anti-tumor immune responses by inducing immunogenic cell death within solid tumors.
What CANDEL THERAPEUTICS INC does
Candel Therapeutics is a clinical-stage biopharmaceutical company developing off-the-shelf viral immunotherapies designed to elicit individualized, systemic anti-tumor immune responses to fight cancer. The company has established two clinical platforms based on genetically modified adenovirus and herpes simplex virus (HSV) constructs, administered locally into tumors to induce immunogenic cell death and trigger both local and systemic (abscopal) immune responses against injected and distant uninjected tumors. The company's lead candidate, aglatimagene besadenovec, is an adenovirus product administered with the prodrug valacyclovir and has demonstrated clinical activity across multiple solid tumor indications, including a recently announced positive Phase 3 trial in localized prostate cancer.
Themes: Viral immunotherapy / oncolytic viruses, Cancer immunotherapy, Immuno-oncology, Personalized / individualized cancer treatment, Cold-to-hot tumor transformation
Fundamentals
- Price$12.86 as of 2026-08-24 close
- Market cap$984M as of 2026-08-24
- 1-year return+116.1% 2025-08-22 close $5.95 → 2026-08-24 close $12.86
- P/En/a negative earnings
- Net margin-15156.5% as of 2026-08-24
- ROE-60.4% as of 2026-08-24
- Debt / equity0.34 as of 2026-08-24
- Revenue CAGR (3y)+0.0% SEC XBRL
- Beta1.77 as of 2026-08-24
- Last reported earnings2026-08-13 SEC EDGAR Form 8-K (Item 2.02)
How CADL compares in its sector
- net profit marginbottom 10% 504 covered Health Care peers, as of 2026-08-24
- operating marginbottom 10% 504 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRbottom 25% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How CANDEL THERAPEUTICS INC looks technically
CANDEL THERAPEUTICS INC (CADL) is trading 84.6% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 71 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 38, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 66, neither overbought (above 70) nor oversold (below 30). It made a new 20-day high about 4 trading days ago.
Trend
8
| Distance from the 200-day | it is trading 84.6% above its 200-day average, the long-term trend line — a longer-term uptrend | +84.6% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $10.17 | $10.17 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $6.97 | $6.97 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing low 26 calendar days ago — the swings before that are what the structure reading is measured on | 26 sessions |
| Wave structure | its recent swings can be read as a completed three-part downward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes below 9.161. It is the only labelling that fits, and it describes the swings already printed, not what comes next. | possible three-wave downward correction, complete |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 71 trading days ago — a "golden cross", a bullish long-term signal | 71 sessions |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 38, with buyers in control | 38.3 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 66, neither overbought (above 70) nor oversold (below 30) | 65.8 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($10.28 to $13.82) — its "stochastic" reading is 73 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 72.9 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 14 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $13.82 | $13.82 |
|---|---|---|
| From the 52-week high | it is 6.9% below its 52-week high (its highest price of the past year) | -7.0% |
| Above the 52-week low | it is 195.6% above its 52-week low (its lowest price of the past year) | +195.6% |
| Below the 52-week high | it is 6.9% below its highest point of the past year | 7.0% |
| Since a 20-day breakout | it made a new 20-day high about 4 trading days ago | 4 sessions |
| Since a 55-day breakout | it made a new 55-day high about 4 trading days ago | 4 sessions |
| All-time high | its highest closing price on record is $14.78 (set on 2021-09-08) | $14.78 |
| Given back of the 52-week move | over the past year its closes ranged ($4.42 to $13.50), and it has given back only a small part of its rise from last year’s low — 7% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $7.60 to $7.89. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 7.0% |
| From the all-time high | it is 13.0% below its all-time high | -13.0% |
| Nearest price level | it is trading 28.6% above a support level at $9.19 — a price it turned at five times since 2025-03-18, most recently on 2026-07-29. Since 2024-08-26 it has 16 such levels below the current price and 0 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -28.6% |
| All-time low | its lowest closing price on record is $0.66 (set on 2023-11-03) | $0.66 |
| Above the all-time low | it is 1848.5% above its all-time low | +1,848% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are wider than usual versus its own recent 6-month history (wider than about 79% of it) | 79th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.7527 between its high and its low — about 5.9% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.7527 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $8.76 and $13.50 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $8.76 – $11.13 – $13.50 |
| Typical daily range (% of price) | its price moves about 5.9% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 5.8% |
| Stretch from the 200-day average | it is trading 7.8 daily ranges above its 200-day average price (84.6% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 7.8 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.74× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 1.8% since the prior reading | +1.8% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | 4 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 4 sessions ago |
|---|---|---|
| Since a bullish engulfing | 5 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 5 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-24 1.1% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | -1.1% |
|---|---|---|
| Open gap | it gapped 2.0% below the previous close 2 sessions ago and has not traded back through the level it left behind at 13.5 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -2.0% |
| Gap filled | a 2.0% gap down opened on 2026-07-28 has been "filled" 19 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 19 sessions ago |
Price streaks
1
| Closing streak | it closed lower in its latest session, after a session that did not close lower — a single down day rather than a run | 1 session down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 31.2 percentage points (the stock gained 34.5% while the market gained 3.3%) | +31.2% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 58.6 percentage points (the stock gained 61.0% while the market gained 2.4%) | +58.6% |
| vs market, 6 months | over the past 6 months this stock beat the market by 141.6 percentage points (the stock gained 152.7% while the market gained 11.1%) | +141.6% |
| vs market, 12 months | over the past 12 months this stock beat the market by 97.8 percentage points (the stock gained 116.1% while the market gained 18.3%) | +97.8% |
Signal agreement
2
| Bullish technical signals | 6 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, MACD momentum is positive, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 6 of 9 |
|---|---|---|
| Bearish technical signals | 0 of the 9 technical signals we can compute for it are currently in a bearish state — these describe past price behaviour, not a forecast | 0 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 32% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-17 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 7.8% of the share price. | +32.0% |
|---|
Volume-weighted price
1
| Vs this year’s average price paid | the price is 67% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $7.71 — a volume-weighted average of daily closes over 158 sessions, not a true tick-by-tick VWAP. | +66.8% |
|---|
Price levels it has turned at before
CADL last closed at $12.86 on 2026-08-24. Since 2024-08-26 it has turned at 16 prices below its last close and 0 above; the 3 nearest below are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $9.19 | Support | 28.6% below the last close | turned there five times · 2025-03-18 to 2026-07-29 |
| $7.68 | Support | 40.3% below the last close | turned there twice · 2024-12-31 to 2026-04-20 |
| $7.27 | Support | 43.5% below the last close | turned there three times · 2024-09-03 to 2025-07-17 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part downward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes below $9.16.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-24.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · in a strong, established uptrend (ADX) · Analyst price target recently RAISED · beating the market · Stretched far above its 200-day average (6+ daily ranges) · Trading above the Ichimoku cloud | Learn: moving average · golden cross · adx · rsi · breakout
Based on daily closing prices as of 2026-08-24. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.22 mean, 1=Strong Buy…5=Strong Sell) — 8 analysts
- Mean price target$20.88 range $12.00 – $29.00; median $22.50
Analyst estimates, as of 2026-08-18. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for CADL
- Consensus EPS estimate-$0.31 next reporting period, as of 2026-08-18
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Clinical development risk: all product candidates are in clinical stages; aglatimagene's Phase 3 prostate cancer trial showed statistically significant but modest DFS improvement (HR 0.70), which may not translate to commercial success or regulatory approval","Regulatory and manufacturing complexity: as a viral vector therapy, the company faces stringent FDA approval pathways and significant manufacturing/GMP challenges for off-the-shelf viral immunotherapies","Significant operating losses and cash burn: the company posted a net loss of $8.9M in Q1 2026 with R&D and G&A expenses of $16.3M; unprofitable with limited revenue, facing runway pressures despite recent capital raises"]
What changed in the latest 10-Q
AI-assisted comparison of CADL's 10-Q filed 2026-05-14 against the prior one filed 2025-11-13.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-05-14) added author attribution 'DeWeess TL et al. Lancet Oncology (In press)' to the phase 3 trial announcement
- Newer filing added clarification that recurrence 'at a microscopic level in prostate biopsies' is linked to biochemical failure
- Newer filing added expanded language: 'independent of the type of EBRT (conventional EBRT vs. moderate hypofractionated EBRT)' to exploratory subset analysis
- Newer filing changed product name presentation from 'CAN-2409 (aglatimagene besadenovec)' to 'aglatimagene besadenovec (referred to herein as aglatimagene and previously as CAN-2409)' with reverse naming order
- Removed:
- Older filing (2025-11-13) included phrase 'Our biological multimodal immunotherapy approach utilizes intratumoral administration of genetically engineered viruses to induce tumor cell death and elicit a systemic anti-tumor response. Local delivery enables us to achieve these effects while aiming to minimize systemic toxicity.' which was removed in newer filing
- Older filing stated 'The FDA previously granted Fast Track Designation' but newer filing states 'The FDA granted Fast Track Designation' (removed 'previously')
- Older filing stated 'intermediate or high-risk' but newer filing states 'intermediate- or high-risk' (hyphenation change)
- Older filing used 'Recurrence beyond two years post-treatment' whereas newer filing specifies 'Recurrence at a microscopic level in prostate biopsies beyond two years post-treatment'
- Older filing stated exploratory subset analysis 'independent of the use of short-term ADT' without mention of EBRT type comparison
- Reworded:
- Product candidate reference changed from 'CAN-2409 (aglatimagene besadenovec), is an off-the-shelf adenovirus product candidate which is administered' to 'aglatimagene besadenovec (referred to herein as aglatimagene and previously as CAN-2409), is an off-the-shelf engineered adenovirus product candidate, administered'
- Clinical trial description changed from 'intermediate-to-high-risk' to 'intermediate- to high-risk' and added '(single high-risk feature)' qualifier
- Description of DFS primary outcome changed from 'for the presence of tumor recurrence' to 'for the microscopic presence of tumor recurrence'
- Changed 'prostate cancer-specific improvement in DFS was observed' to 'improvement in prostate cancer-specific DFS was observed'
- Changed 'was observed in the CAN-2409 arm' to omit 'observed' in PSA nadir statement
- Changed 'observed in the control arm' to no text modification for pathological complete response (older had 'observed')
- Notes:
- The newer filing text ends mid-sentence ('Aglatimagene was generally well tolera') making full comparison of adverse events section incomplete
- Both filings reference December 2024 announcement of positive topline data, confirming temporal consistency
- Changes primarily reflect naming convention standardization and clarification of clinical trial details rather than substantive trial result changes
Risk Factors
- Added:
- Newer filing shows Item 1A Risk Factors page number as 37 (previously 36 in older filing)
- Newer filing contains financial statements as of March 31, 2026 and December 31, 2025; older filing as of September 30, 2025 and December 31, 2024
- Newer filing shows 'Grant income' of $22K in Q1 2026 three-month period (not present in older filing's comparable Q1 2025 period)
- Newer filing includes public offering activity: 'Issuance of common stock in public offering, net of issuance costs of $6.5 million' for 18,348,624 shares generating $93,488K net
- Newer filing shows warrant liabilities decreased from $15,598K (Dec 31, 2025) to $7,955K (Mar 31, 2026)
- Newer filing reflects change in fair value of warrant liabilities as income of $7,643K in Q1 2026 (compared to $14,881K in Q1 2025)
- Removed:
- Older filing included 'Current portion of term loan payable to a bank' line item ($4,225K at Sept 30, 2025) shown separately; newer filing shows 'Term loan' as single line ($46,428K at Mar 31, 2026)
- Older filing showed 'Warrant liability' as separate current liability line; newer filing combines as 'Warrant liabilities' in non-current presentation
- Older filing presented nine-month and quarterly comparative periods for operations statement; newer filing shows only three-month comparison (Q1 2026 vs Q1 2025)
- Older filing included 'Impairment of fixed assets' ($83K) and 'Loss on the sale and disposal of fixed assets' ($339K) in cash flow statement; these items absent from newer filing period
- Older filing cash flow statement showed 'Principal payments on term loan' ($2,500K in nine months 2024); newer filing Q1 2026 shows no such principal payments
- Reworded:
- Older filing title: 'Statements of Operations and Comprehensive Loss'; newer filing: 'Statements of Operations and Comprehensive Income (Loss)' – reflects change from loss to income presentation
- Older filing stockholders' equity statement header: 'Stockholders' Equity (Deficit)'; newer filing: 'Stockholders' Equity' – reflects positive equity position
- Newer filing shows separate 'Other long-term debt' ($1,047K) distinct from term loan; older filing labeled similar item within term loan structure
- Newer filing cash flow shows 'Proceeds from issuance of common stock in public offering, net of issuance costs' as $93,787K; older filing shows 'Proceeds from sale of common stock through at-the-market offerings' structure
- Notes:
- Newer filing appears truncated at end of organizational note; full text not provided for complete comparison of notes disclosure changes
- Document page numbers differ between filings but item numbering structure is consistent
- Financial statement comparison spans different quarters (Q1 2026 vs Q1 2025 for newer; nine-month 2025 vs 2024 for older), affecting direct period-to-period comparisons
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 2 open-market sales by insiders in the last 90 days.
- Last 90 days0 buys · 2 sells ($305920) — 2 selling insiders
- Last 180 days0 buys · 2 sells ($305920) — 2 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-06-29. As of 2026-08-25.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about CADL's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding CADL as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 15,054,163
- Reported value $73,765,400
reported quarterly holdings change (2025-12-31 → 2026-03-31): 1 new, 3 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
CADL had 12,655,457 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
CADL had 16.5% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 10.41 days to cover at the same settlement.
- Reported short interest (shares) 12,655,457
- Short interest (% of shares outstanding) 16.5%
- Prior settlement (shares) 12,961,675
- Reported change -2.36%
- Days to cover (reported) 10.41
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Amgen (AMGN)
- Merck & Co. (MRK)
- Bristol Myers Squibb (BMY)
- Replimune Group (REPL)
- Adaptimmune Therapeutics (ADAP)
- Oncolytics Biotech (ONCY)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare CADL vs…
CANDEL THERAPEUTICS INC is found in…
Frequently asked questions
What does CANDEL THERAPEUTICS INC (CADL) do?
Candel Therapeutics is a clinical-stage biopharmaceutical company developing off-the-shelf viral immunotherapies designed to elicit individualized, systemic anti-tumor immune responses to fight cancer. The company has established two clinical platforms based on genetically modified adenovirus and herpes simplex virus (HSV) constructs, administered locally into tumors to induce immunogenic cell death and trigger both local and systemic (abscopal) immune responses against injected and distant…
What sector is CANDEL THERAPEUTICS INC (CADL) in?
CANDEL THERAPEUTICS INC (CADL) is classified in the Health Care sector. Its industry is Viral immunotherapy / immuno-oncology. It trades on NASDAQ.
Who are CANDEL THERAPEUTICS INC's (CADL) competitors?
Notable peers of CANDEL THERAPEUTICS INC (CADL) include Amgen, Merck & Co., Bristol Myers Squibb, Replimune Group and Adaptimmune Therapeutics. This peer set is informational only — not financial advice.
Is CANDEL THERAPEUTICS INC (CADL) overbought or oversold right now?
CANDEL THERAPEUTICS INC (CADL) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 66, in the neutral middle (as of 2026-08-24). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on CADL come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-24.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.